BioLife Solutions - BLFS Stock Forecast, Price & News

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $25.35 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.54 and a current ratio of 3.55. The business has a 50-day moving average of $17.27 and a two-hundred day moving average of $18.71. BioLife Solutions has a 12 month low of $10.40 and a 12 month high of $60.67.

Analyst Ratings Changes

Several research firms recently commented on BLFS. Maxim Group dropped their target price on BioLife Solutions from $60.00 to $30.00 in a research note on Thursday, May 12th. Oppenheimer upgraded BioLife Solutions from a "market perform" rating to an "outperform" rating in a research note on Monday, April 25th. Cowen dropped their target price on BioLife Solutions from $50.00 to $32.00 in a research note on Tuesday, May 10th. B. Riley dropped their price target on BioLife Solutions from $48.00 to $34.00 in a research note on Tuesday, May 17th. Finally, Cowen dropped their price target on BioLife Solutions to $29.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.00.

Insider Transactions at BioLife Solutions

In other news, COO Greef Roderick De sold 9,158 shares of the company's stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total value of $144,604.82. Following the completion of the sale, the chief operating officer now owns 124,458 shares of the company's stock, valued at $1,965,191.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, COO Greef Roderick De sold 9,158 shares of the company's stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total value of $144,604.82. Following the completion of the sale, the chief operating officer now owns 124,458 shares of the company's stock, valued at $1,965,191.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CRO Marcus Schulz sold 4,600 shares of the company's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.03, for a total value of $92,138.00. Following the completion of the sale, the executive now directly owns 36,218 shares of the company's stock, valued at approximately $725,446.54. The disclosure for this sale can be found here. Insiders sold 19,602 shares of company stock valued at $330,022 over the last quarter. Company insiders own 3.30% of the company's stock.